COMy 2023 | Using MRD to improve prognostication during the maintenance phase of myeloma treatment
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the dynamics of measurable residual disease (MRD) in patients undergoing treatment for multiple myeloma (MM). According to growing amounts of data, patient MRD status is more dynamic than previously perceived, often with frequent fluctuations between negative and positive MRD. This volatility significantly affects the probability of progression-free survival (PFS); thus, Dr Paiva emphasizes the importance of performing MRD assessment at multiple timepoints to improve prognostication. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
